IGF signaling pathway as a selective target of familial breast cancer therapy.
Hereditary breast cancers affect women who have an increased risk of developing tumors because of a familial history. In most cases, they can be attributed to mutations in the breast cancer associated gene 1 and 2 (BRCA1 and BRCA2). Recent studies have demonstrated a link between the insulin-like growth factor (IGF) signaling pathway and familial breast cancer incidence. IGF and IGF receptors represent a family of biological growth factors and transducers, which have been involved in both physiological and pathological processes. It has been shown that BRCA1 regulates expression of several members of the IGF family. Here, we will examine our understanding of the functions of IGF/IGF-receptor signaling, the development of new inhibitors of this pathway and the related mechanisms of familial breast cancer formation.
Shukla
Vivek
V
Genetics of Development and Disease Branch, 10/9N105, Diabetes Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Coumoul
Xavier
X
Vassilopoulos
Athanassios
A
Deng
Chu-Xia
CX
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D019398:Genes, BRCA1; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D051379:Mice; D008954:Models, Biological; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D034741:RNA, Small Interfering / Q000235:genetics; D017451:Receptors, Somatomedin / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013002:Somatomedins / Q000037:antagonists & inhibitors / Q000502:physiology*
D000911:Antibodies, Monoclonal; D047428:Protein Kinase Inhibitors; D034741:RNA, Small Interfering; D017451:Receptors, Somatomedin; D013002:Somatomedins